LGM
LRMR icon

Logos Global Management’s Larimar Therapeutics LRMR Stock Holding History

Logos Global Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-230,000
Closed -$3.36M – 64
2021
Q1 		$3.36M Sell
230,000
-485,000
-68% -$8.81M 0.33% 38
2020
Q4 		$15.3M Buy
715,000
+385,000
+117% +$7.72M 1.31% 18
2020
Q3 		$5.01M Buy
330,000
+272,525
+474% +$3.45M 0.64% 30
2020
Q2 		$739K Buy
+57,475
New +$669K 0.15% 44

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Logos Global Management's LRMR Position: Q2 2021 in Review

Logos Global Management sold out of Larimar Therapeutics (LRMR) in Q2 2021, closing a stake of 230,000 shares — an estimated $3.36M sold.

Logos Global Management first reported a position in LRMR in Q2 2020 and held it in 4 quarters. The position peaked at $15.3M in Q4 2020. 45 funds tracked by Wall St. Rank hold LRMR as of Q2 2021.

  • Logos Global Management reported no remaining Larimar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Logos Global Management sold 230,000 Larimar Therapeutics shares in Q2 2021, an estimated $3.36M.
  • Logos Global Management first reported a position in Larimar Therapeutics in Q2 2020 and held it in 4 quarters.
  • Logos Global Management's Larimar Therapeutics position peaked at $15.3M in Q4 2020.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2021.

Based on Logos Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.